首页 > 最新文献

Journal of Research in Pharmacy Practice最新文献

英文 中文
The Effect of Consuming Chicory Juice by Breastfeeding Mothers on Neonatal Icterus. 母乳喂养母亲饮用菊苣汁对新生儿黄疸的影响。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-18 eCollection Date: 2022-01-01 DOI: 10.4103/jrpp.jrpp_98_21
Shahla Vaziri Esfarjani, Shadi Zinatian, Mahin Salimi

Objective: Hyperbilirubinemia has been considered one of the most common clinical conditions in newborn babies. As a traditional medicine, chicory distillate may be beneficial in reducing bilirubin. This randomized, double-blind clinical trial was conducted to determine the effect of chicory extract on hyperbilirubinemia in neonates.

Methods: The clinical trial was conducted among 154 participants with hyperbilirubinemia. The study group was selected and randomly divided into the control (n = 77) and intervention (n = 77) groups. In the intervention group, breastfeeding women received a 10% solution of chicory distillate (50 ml every 12 h), whereas, in the control group, the participants received sterile distilled water, 50 ml every 12 h. The infants' bilirubin level was measured before and 24, 48, and 72 h after the intervention. Fisher's exact and Chi-square tests were run to examine qualitative data, while a t-test was applied for independent variables.

Findings: There was a significant difference between the intervention and control groups (P < 0.001). Within each group, a significant difference was found in bilirubin levels among different sampling times (P < 0.001). Although the bilirubin levels reduced during the time intervals in both groups, the reduction rate was significantly higher in the intervention group (P < 0.001). Based on the results, breastfeeding mothers should be aware of including chicory extract in their nutritional programs.

Conclusion: Chicory extract consumption in breastfeeding mothers can reduce bilirubin in their neonate.

目的:高胆红素血症被认为是新生儿最常见的临床疾病之一。菊苣提取物作为一种传统药物,可能具有降低胆红素的作用。本随机双盲临床试验旨在确定菊苣提取物对新生儿高胆红素血症的影响。方法:对154例高胆红素血症患者进行临床试验。选取研究组,随机分为对照组(n = 77)和干预组(n = 77)。在干预组中,母乳喂养的妇女接受10%的菊苣馏出物溶液(每12小时50毫升),而在对照组中,参与者接受无菌蒸馏水,每12小时50毫升。在干预前和干预后24、48和72小时测量婴儿的胆红素水平。采用Fisher精确检验和卡方检验检验定性数据,采用t检验检验自变量。结果:干预组与对照组比较差异有统计学意义(P < 0.001)。在每组内,不同采样时间的胆红素水平有显著差异(P < 0.001)。虽然两组的胆红素水平在时间间隔内均有所降低,但干预组的降低率明显高于干预组(P < 0.001)。根据研究结果,母乳喂养的母亲应该注意在营养计划中加入菊苣提取物。结论:哺乳母亲食用菊苣提取物可降低新生儿胆红素水平。
{"title":"The Effect of Consuming Chicory Juice by Breastfeeding Mothers on Neonatal Icterus.","authors":"Shahla Vaziri Esfarjani,&nbsp;Shadi Zinatian,&nbsp;Mahin Salimi","doi":"10.4103/jrpp.jrpp_98_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_98_21","url":null,"abstract":"<p><strong>Objective: </strong>Hyperbilirubinemia has been considered one of the most common clinical conditions in newborn babies. As a traditional medicine, chicory distillate may be beneficial in reducing bilirubin. This randomized, double-blind clinical trial was conducted to determine the effect of chicory extract on hyperbilirubinemia in neonates.</p><p><strong>Methods: </strong>The clinical trial was conducted among 154 participants with hyperbilirubinemia. The study group was selected and randomly divided into the control (<i>n</i> = 77) and intervention (<i>n</i> = 77) groups. In the intervention group, breastfeeding women received a 10% solution of chicory distillate (50 ml every 12 h), whereas, in the control group, the participants received sterile distilled water, 50 ml every 12 h. The infants' bilirubin level was measured before and 24, 48, and 72 h after the intervention. Fisher's exact and Chi-square tests were run to examine qualitative data, while a <i>t</i>-test was applied for independent variables.</p><p><strong>Findings: </strong>There was a significant difference between the intervention and control groups (<i>P</i> < 0.001). Within each group, a significant difference was found in bilirubin levels among different sampling times (<i>P</i> < 0.001). Although the bilirubin levels reduced during the time intervals in both groups, the reduction rate was significantly higher in the intervention group (<i>P</i> < 0.001). Based on the results, breastfeeding mothers should be aware of including chicory extract in their nutritional programs.</p><p><strong>Conclusion: </strong>Chicory extract consumption in breastfeeding mothers can reduce bilirubin in their neonate.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 1","pages":"40-43"},"PeriodicalIF":1.0,"publicationDate":"2022-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/88/JRPP-11-40.PMC9585807.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40655551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Development of a Web-Based Virtual Simulated Learning Environment for Pharmacy Practice Education. 基于web的药学实践教育虚拟模拟学习环境的开发。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-18 eCollection Date: 2022-01-01 DOI: 10.4103/jrpp.jrpp_34_22
Arash Najimi, Shirinsadat Badri, Mahdiyeh Azizkhani, Samaneh Zolghadr, Shaghayegh Roofeh, Sayyed Ali Sepehr, Sajjad Mohammadi

Objective: In the present study, we aimed to develop a virtual simulation that allows pharmacy students to play through actual prescriptions and pharmacy practice scenarios productively and on a personal computer. If designed properly, this program may serve as a supplementary educational tool without the need for an existing human tutor that could provide learning outcomes as good as those resulting from traditional paper-based pharmacy practice tutorials.

Methods: A computer-based simulation of a community pharmacy was developed. This program mainly targeted three basic learning needs of pharmacy students: drug dispensing, patient counseling, and dealing with clinical situations related to the patients' prescription or demand for over-the-counter (OTC) recommendations. Fundamental design decisions were based on breaking down the dispensing process into logical components to provide discrete development elements. For teaching patient counseling and clinical skills, instructors wrote scenarios covering the most prevalent pharmacy practice issues, mainly focused on medication use during pregnancy or lactation, OTC recommendations, information related to drug interactions and adverse drug reactions, and interactions between prescription drugs and patient's underlying disease.

Findings: Based on the primary curriculum topics, the development team designed exercises for pharmacy practice units presented to year 5 pharmacy students. Accordingly, exercises were developed to authentically reflect tasks and challenges a community pharmacist would regularly face in the workplace. To fulfill this part, over 2000 real prescriptions were scanned and categorized based on the main drugs included. These prescriptions were used for both activities, namely medication dispensing and clinical scenarios. Furthermore, five senior pharmacy students wrote more than 200 clinical scenarios under a clinical pharmacist's supervision. The main objectives of pharmacy practice courses were followed to cover the most important must-to-know clinical tips, whether related to giving relevant advice as an OTC recommendation, referring the patient to a primary care physician, or just providing a piece of general health advice, which is expected to be comprehensively learned by pharmacy students.

Conclusion: This program was designed as a simulated learning environment to help students develop prescription dispensing and clinical skills. To be considered a success, this simulation needed to provide equivalent or better learning outcomes than the current practice approach, which should be assessed in the future evaluation of the software, and then be promoted accordingly.

目的:在本研究中,我们旨在开发一个虚拟模拟,使药学学生能够在个人电脑上有效地玩实际处方和药学实践场景。如果设计得当,这个程序可以作为一种补充教育工具,而不需要一个现有的人类导师,可以提供像传统的纸质药房实践教程那样好的学习成果。方法:开发了一种基于计算机的社区药房模拟系统。该项目主要针对药学专业学生的三个基本学习需求:药品调剂、患者咨询、处理与患者处方或非处方(OTC)建议需求相关的临床情况。基本的设计决策是基于将分配过程分解为逻辑组件,以提供离散的开发元素。为了教授患者咨询和临床技能,讲师编写了涵盖最普遍的药房实践问题的场景,主要集中在怀孕或哺乳期间的药物使用,OTC建议,药物相互作用和药物不良反应相关信息,以及处方药与患者潜在疾病之间的相互作用。研究结果:基于小学课程主题,开发团队设计了面向五年级药学学生的药学实践单元练习。因此,开发的练习真实地反映了社区药剂师在工作场所经常面临的任务和挑战。为了完成这一部分,我们对2000多张真实处方进行了扫描,并根据所包含的主要药物进行了分类。这些处方用于两种活动,即药物分配和临床场景。五名药学专业高年级学生在临床药师的指导下撰写了200多篇临床场景。药学实践课程的主要目标是涵盖最重要的必须知道的临床技巧,无论是提供相关的建议作为OTC建议,还是将患者转介给初级保健医生,或者只是提供一条一般的健康建议,这些都希望药学学生能够全面学习。结论:本课程设计为一个模拟学习环境,帮助学生发展处方配药和临床技能。要被认为是成功的,这个模拟需要提供与当前实践方法相当或更好的学习结果,这应该在未来的软件评估中进行评估,然后相应地进行推广。
{"title":"Development of a Web-Based Virtual Simulated Learning Environment for Pharmacy Practice Education.","authors":"Arash Najimi,&nbsp;Shirinsadat Badri,&nbsp;Mahdiyeh Azizkhani,&nbsp;Samaneh Zolghadr,&nbsp;Shaghayegh Roofeh,&nbsp;Sayyed Ali Sepehr,&nbsp;Sajjad Mohammadi","doi":"10.4103/jrpp.jrpp_34_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_34_22","url":null,"abstract":"<p><strong>Objective: </strong>In the present study, we aimed to develop a virtual simulation that allows pharmacy students to play through actual prescriptions and pharmacy practice scenarios productively and on a personal computer. If designed properly, this program may serve as a supplementary educational tool without the need for an existing human tutor that could provide learning outcomes as good as those resulting from traditional paper-based pharmacy practice tutorials.</p><p><strong>Methods: </strong>A computer-based simulation of a community pharmacy was developed. This program mainly targeted three basic learning needs of pharmacy students: drug dispensing, patient counseling, and dealing with clinical situations related to the patients' prescription or demand for over-the-counter (OTC) recommendations. Fundamental design decisions were based on breaking down the dispensing process into logical components to provide discrete development elements. For teaching patient counseling and clinical skills, instructors wrote scenarios covering the most prevalent pharmacy practice issues, mainly focused on medication use during pregnancy or lactation, OTC recommendations, information related to drug interactions and adverse drug reactions, and interactions between prescription drugs and patient's underlying disease.</p><p><strong>Findings: </strong>Based on the primary curriculum topics, the development team designed exercises for pharmacy practice units presented to year 5 pharmacy students. Accordingly, exercises were developed to authentically reflect tasks and challenges a community pharmacist would regularly face in the workplace. To fulfill this part, over 2000 real prescriptions were scanned and categorized based on the main drugs included. These prescriptions were used for both activities, namely medication dispensing and clinical scenarios. Furthermore, five senior pharmacy students wrote more than 200 clinical scenarios under a clinical pharmacist's supervision. The main objectives of pharmacy practice courses were followed to cover the most important must-to-know clinical tips, whether related to giving relevant advice as an OTC recommendation, referring the patient to a primary care physician, or just providing a piece of general health advice, which is expected to be comprehensively learned by pharmacy students.</p><p><strong>Conclusion: </strong>This program was designed as a simulated learning environment to help students develop prescription dispensing and clinical skills. To be considered a success, this simulation needed to provide equivalent or better learning outcomes than the current practice approach, which should be assessed in the future evaluation of the software, and then be promoted accordingly.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 1","pages":"44-49"},"PeriodicalIF":1.0,"publicationDate":"2022-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/eb/JRPP-11-44.PMC9585801.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40677569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients' Knowledge and Practice on Disposal of Medicines Kept in Households in South Africa: Findings and Implications. 南非患者对家庭药品处置的知识和实践:调查结果和影响。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-18 eCollection Date: 2022-01-01 DOI: 10.4103/jrpp.jrpp_85_21
Kesentseng Jackson Mahlaba, Elvera Anna Helberg, Brian Godman, Amanj Kurdi, Johanna Catharina Meyer

Objective: The disposal of unwanted, unused, or expired medicines is a concern. Currently, there is little knowledge regarding their disposal among patients in South Africa. Consequently, there is a need to address this.

Methods: This was a descriptive and quantitative study with patients conducted among 16 primary health-care clinics (PHCs) in South Africa. A structured questionnaire was administered to 171 conveniently selected patients. Data on ideal disposal methods were collected and compared to actual disposal practices.

Findings: 74.9% of patients reported having unused medicines at home, of whom 34.4% wanted these medicines disposed of. However, 64.9% did not know how to dispose of them, with 95.3% reporting having never been informed by health-care professionals of disposal methods. While patients prefer to return medicines to their PHC, only 7.0% did so. Patients' ideal disposal practices included designated collection task teams (25.1%) and dissolving their unused medicines in water (38.6%). However, current practices indicated that patients flushed medicines down the sewer (31.6%) or disposed of them in municipal bins (23.9%).

Conclusion: Patients disposed of their unwanted medicines using incorrect disposal techniques, which they thought were correct. This urgently needs to be addressed.

目的:不需要的、未使用的或过期药品的处理是一个值得关注的问题。目前,对南非患者如何处置这些药物知之甚少。因此,有必要解决这个问题。方法:对南非16家初级卫生保健诊所(PHCs)的患者进行描述性和定量研究。对171名方便选择的患者进行结构化问卷调查。收集了理想处置方法的数据,并与实际处置做法进行了比较。结果:74.9%的患者报告家中有未使用的药物,其中34.4%的患者希望将这些药物处理掉。然而,64.9%的人不知道如何处理,95.3%的人报告从未被卫生保健专业人员告知处理方法。虽然患者倾向于将药物归还给初级保健诊所,但只有7.0%的患者这样做了。患者的理想处理方法包括指定收集任务小组(25.1%)和将未使用的药物溶解在水中(38.6%)。然而,目前的做法表明,患者将药物冲入下水道(31.6%)或将其丢弃在城市垃圾箱中(23.9%)。结论:患者使用了错误的处理方法处理不需要的药品,他们认为这些处理方法是正确的。这一问题亟需解决。
{"title":"Patients' Knowledge and Practice on Disposal of Medicines Kept in Households in South Africa: Findings and Implications.","authors":"Kesentseng Jackson Mahlaba,&nbsp;Elvera Anna Helberg,&nbsp;Brian Godman,&nbsp;Amanj Kurdi,&nbsp;Johanna Catharina Meyer","doi":"10.4103/jrpp.jrpp_85_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_85_21","url":null,"abstract":"<p><strong>Objective: </strong>The disposal of unwanted, unused, or expired medicines is a concern. Currently, there is little knowledge regarding their disposal among patients in South Africa. Consequently, there is a need to address this.</p><p><strong>Methods: </strong>This was a descriptive and quantitative study with patients conducted among 16 primary health-care clinics (PHCs) in South Africa. A structured questionnaire was administered to 171 conveniently selected patients. Data on ideal disposal methods were collected and compared to actual disposal practices.</p><p><strong>Findings: </strong>74.9% of patients reported having unused medicines at home, of whom 34.4% wanted these medicines disposed of. However, 64.9% did not know how to dispose of them, with 95.3% reporting having never been informed by health-care professionals of disposal methods. While patients prefer to return medicines to their PHC, only 7.0% did so. Patients' ideal disposal practices included designated collection task teams (25.1%) and dissolving their unused medicines in water (38.6%). However, current practices indicated that patients flushed medicines down the sewer (31.6%) or disposed of them in municipal bins (23.9%).</p><p><strong>Conclusion: </strong>Patients disposed of their unwanted medicines using incorrect disposal techniques, which they thought were correct. This urgently needs to be addressed.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 1","pages":"13-18"},"PeriodicalIF":1.0,"publicationDate":"2022-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/68/63/JRPP-11-13.PMC9585805.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40655550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Self-Medication with Modern and Complementary Alternative Medicines in Patients with Chronic Pain. 慢性疼痛患者的自我药疗与现代和补充替代药物。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-18 eCollection Date: 2022-01-01 DOI: 10.4103/jrpp.jrpp_14_22
Indu Jangra, Ashok Kumar Dubey, Ekta Arora, Basit Iqbal Peerzada

Objective: The study aimed to assess the prevalence, pattern, and determinants of the self-medication practices with modern and/or complementary and alternative medicine (CAM) therapies in patients with chronic pain.

Methods: The descriptive cross-sectional study was conducted between August 2021 and January 2022 and assessed a representative sample of chronic pain patients visiting outpatient departments in India by administering a semi-structured questionnaire. The survey questionnaire consisted of forty multiple response items, including ten questions that assessed the subjects' sociodemographic profile, for example, age, sex, education, marital status, employment status, residence, and distance of home from any health care facility. The next part of the questionnaire evaluated the practice and determinants of self-medication for chronic pain with modern or CAM therapies. It included thirty questions assessing the reasons, duration, sources of information, procurement methods, preference for a particular system of medicine, knowledge about risks or drug interactions, rationality, perception of the subject, and communication with the physician, among other aspects of self-medication for pain.

Findings: Out of the 325 respondents with chronic pain, those who practiced self-medication (237) were significantly more in number than those who did not (P < 0.05). Among those who self-medicated, the practice was significantly higher in urban participants living closer to healthcare facilities, with better economic backgrounds and higher education (P < 0.05). Modern medicine was the predominant choice of self-treatment for chronic pain compared to various CAM therapies (P < 0.05). Among the alternatives, homeopathic and ayurvedic systems of medicines were preferred. The main reasons for self-medicating were urgency, ease, previous prescriptions, and presumed mildness of the underlying disease. More than one-third of the respondents opined in favor of continuing self-medication in the future.

Conclusion: The prevalent practice of self-medication for chronic pain may not be hazardous, but it can turn into a serious problem if not based on correct information. The inherent risks need to be minimized by increasing awareness, health education, and pharmacy regulations.

目的:本研究旨在评估慢性疼痛患者采用现代和/或补充和替代医学(CAM)疗法进行自我药疗的流行程度、模式和决定因素。方法:描述性横断面研究于2021年8月至2022年1月进行,并通过管理半结构化问卷对印度门诊慢性疼痛患者的代表性样本进行评估。调查问卷由40个多重回答项目组成,其中10个问题评估了受试者的社会人口特征,例如年龄、性别、教育程度、婚姻状况、就业状况、居住地以及家与任何医疗机构的距离。问卷的下一部分评估的做法和决定因素自我药物治疗慢性疼痛与现代或CAM疗法。它包括30个问题,评估原因、持续时间、信息来源、采购方法、对特定药物系统的偏好、对风险或药物相互作用的了解、合理性、对主题的感知、与医生的沟通,以及自我治疗疼痛的其他方面。结果:325例慢性疼痛患者中,自我药疗者237例,明显多于未自我药疗者(P < 0.05)。在自我用药的人群中,居住在离医疗机构较近、经济背景较好、受教育程度较高的城市参与者的自我用药率显著较高(P < 0.05)。自我治疗慢性疼痛的选择以现代医学为主(P < 0.05)。在替代方案中,顺势疗法和阿育吠陀系统的药物是首选。自我用药的主要原因是紧急、方便、既往处方和假定的基础疾病轻微。超过三分之一的受访者赞成未来继续自我药物治疗。结论:对慢性疼痛进行自我药疗的普遍做法可能并不危险,但如果不基于正确的信息,可能会变成一个严重的问题。需要通过提高认识、开展健康教育和制定药学法规,将固有风险降至最低。
{"title":"Self-Medication with Modern and Complementary Alternative Medicines in Patients with Chronic Pain.","authors":"Indu Jangra,&nbsp;Ashok Kumar Dubey,&nbsp;Ekta Arora,&nbsp;Basit Iqbal Peerzada","doi":"10.4103/jrpp.jrpp_14_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_14_22","url":null,"abstract":"<p><strong>Objective: </strong>The study aimed to assess the prevalence, pattern, and determinants of the self-medication practices with modern and/or complementary and alternative medicine (CAM) therapies in patients with chronic pain.</p><p><strong>Methods: </strong>The descriptive cross-sectional study was conducted between August 2021 and January 2022 and assessed a representative sample of chronic pain patients visiting outpatient departments in India by administering a semi-structured questionnaire. The survey questionnaire consisted of forty multiple response items, including ten questions that assessed the subjects' sociodemographic profile, for example, age, sex, education, marital status, employment status, residence, and distance of home from any health care facility. The next part of the questionnaire evaluated the practice and determinants of self-medication for chronic pain with modern or CAM therapies. It included thirty questions assessing the reasons, duration, sources of information, procurement methods, preference for a particular system of medicine, knowledge about risks or drug interactions, rationality, perception of the subject, and communication with the physician, among other aspects of self-medication for pain.</p><p><strong>Findings: </strong>Out of the 325 respondents with chronic pain, those who practiced self-medication (237) were significantly more in number than those who did not (<i>P</i> < 0.05). Among those who self-medicated, the practice was significantly higher in urban participants living closer to healthcare facilities, with better economic backgrounds and higher education (<i>P</i> < 0.05). Modern medicine was the predominant choice of self-treatment for chronic pain compared to various CAM therapies (<i>P</i> < 0.05). Among the alternatives, homeopathic and ayurvedic systems of medicines were preferred. The main reasons for self-medicating were urgency, ease, previous prescriptions, and presumed mildness of the underlying disease. More than one-third of the respondents opined in favor of continuing self-medication in the future.</p><p><strong>Conclusion: </strong>The prevalent practice of self-medication for chronic pain may not be hazardous, but it can turn into a serious problem if not based on correct information. The inherent risks need to be minimized by increasing awareness, health education, and pharmacy regulations.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 1","pages":"19-24"},"PeriodicalIF":1.0,"publicationDate":"2022-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/9f/JRPP-11-19.PMC9585802.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40677110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Evaluation of COVID-19 Treatments in Iran in Comparison with Local Therapeutic Recommendations: A Population-Level Study on Utilization and Costs of Prescription Drugs. 伊朗COVID-19治疗与当地治疗建议的比较评估:一项关于处方药使用和成本的人口水平研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-18 eCollection Date: 2022-01-01 DOI: 10.4103/jrpp.jrpp_6_22
Amir Hashemi-Meshkini, Reza Koochak, Shekoufeh Nikfar, Ehsan Rezaei-Darzi, Saeed Yaghoubifard

Objective: In this study, we assess population-level data of COVID-19 treatments in Iran compared to Ministry of Health (MOH)-published guidelines to gain a better insight into the quality of care for this disease.

Methods: National sales data of each recommended and nonrecommended COVID-19 medicine were used to proxy utilization between March 21, 2020, and March 21, 2021, or Iranian year 1399. COVID-19-attributed sales volume and number of patients were estimated by adjusting sales data with pre-COVID-19 average growth rate, recommended dose, and duration of treatment. Next, they were compared with the MOH guidelines in outpatient and inpatient settings. Furthermore, the list of top 10 molecules of the market and top 10 COVID-19-indicated molecules in terms of values were extracted to assess the economic burden of COVID-19 prescription drugs and their share.

Findings: The estimated number of patients receiving COVID-19 treatments in some outpatient medicines such as recommended hydroxychloroquine was over 2.2 million. Favipiravir and remdesivir were collectively about two inpatient medicines 260,000; however, neither of these two medicines was recommended in the MOH guidelines. In some fewer specific medicines such as dexamethasone, prednisolone, azithromycin, and naproxen, the estimated number of COVID-19-attributed patients were incomparable with the officially announced number of confirmed cases in the year of study, which could be related to nonconfirmed diagnosed cases, irrational use, or prescribing, or limitations of our data and study. The total COVID-19-attributed market of candidate medicines was over 15 trillion IR Rials (almost 4.3% of the total market). Remdesivir, with over 60% of the total COVID-19 attributed market, followed by favipiravir, was among the highest value medicines.

Conclusion: Despite the release of the COVID-19 guideline by Iran MOH, misalignment in the enforcement of decisions was a serious weakness (cases of favipiravir and remdesivir). This weakness led to some economic burden on the health-care system and raised ethical concerns.

目的:在本研究中,我们将伊朗COVID-19治疗的人口水平数据与卫生部(MOH)公布的指南进行比较,以更好地了解这种疾病的护理质量。方法:采用2020年3月21日至2021年3月21日或伊朗年1399年期间全国各推荐和非推荐COVID-19药物的销售数据进行代理使用。根据新冠肺炎前的平均增长率、推荐剂量和治疗时间调整销售数据,估算新冠肺炎相关销售额和患者人数。接下来,将它们与卫生部门诊和住院指导方针进行比较。提取市场前10大分子和价值前10大COVID-19指示分子清单,评估COVID-19处方药的经济负担及其份额。结果:门诊接受羟氯喹等推荐药物治疗的患者估计超过220万。法匹拉韦和瑞德西韦两种住院药物共26万;然而,这两种药物都没有在卫生部指南中推荐。在地塞米松、强的松龙、阿奇霉素、萘普生等特异性较弱的药物中,估计的新冠肺炎患者数与研究年度官方公布的确诊病例数无法比较,这可能与未确诊病例、不合理使用或处方有关,也可能与我们的数据和研究的局限性有关。covid -19相关候选药物的总市场超过15万亿里亚尔(几乎占总市场的4.3%)。Remdesivir占COVID-19总市场的60%以上,其次是favipiravir,是价值最高的药物之一。结论:尽管伊朗卫生部发布了COVID-19指南,但执行决定的不一致是一个严重的弱点(favipiravir和remdesivir的案例)。这一弱点给卫生保健系统带来了一些经济负担,并引发了伦理问题。
{"title":"Evaluation of COVID-19 Treatments in Iran in Comparison with Local Therapeutic Recommendations: A Population-Level Study on Utilization and Costs of Prescription Drugs.","authors":"Amir Hashemi-Meshkini,&nbsp;Reza Koochak,&nbsp;Shekoufeh Nikfar,&nbsp;Ehsan Rezaei-Darzi,&nbsp;Saeed Yaghoubifard","doi":"10.4103/jrpp.jrpp_6_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_6_22","url":null,"abstract":"<p><strong>Objective: </strong>In this study, we assess population-level data of COVID-19 treatments in Iran compared to Ministry of Health (MOH)-published guidelines to gain a better insight into the quality of care for this disease.</p><p><strong>Methods: </strong>National sales data of each recommended and nonrecommended COVID-19 medicine were used to proxy utilization between March 21, 2020, and March 21, 2021, or Iranian year 1399. COVID-19-attributed sales volume and number of patients were estimated by adjusting sales data with pre-COVID-19 average growth rate, recommended dose, and duration of treatment. Next, they were compared with the MOH guidelines in outpatient and inpatient settings. Furthermore, the list of top 10 molecules of the market and top 10 COVID-19-indicated molecules in terms of values were extracted to assess the economic burden of COVID-19 prescription drugs and their share.</p><p><strong>Findings: </strong>The estimated number of patients receiving COVID-19 treatments in some outpatient medicines such as recommended hydroxychloroquine was over 2.2 million. Favipiravir and remdesivir were collectively about two inpatient medicines 260,000; however, neither of these two medicines was recommended in the MOH guidelines. In some fewer specific medicines such as dexamethasone, prednisolone, azithromycin, and naproxen, the estimated number of COVID-19-attributed patients were incomparable with the officially announced number of confirmed cases in the year of study, which could be related to nonconfirmed diagnosed cases, irrational use, or prescribing, or limitations of our data and study. The total COVID-19-attributed market of candidate medicines was over 15 trillion IR Rials (almost 4.3% of the total market). Remdesivir, with over 60% of the total COVID-19 attributed market, followed by favipiravir, was among the highest value medicines.</p><p><strong>Conclusion: </strong>Despite the release of the COVID-19 guideline by Iran MOH, misalignment in the enforcement of decisions was a serious weakness (cases of favipiravir and remdesivir). This weakness led to some economic burden on the health-care system and raised ethical concerns.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 1","pages":"1-7"},"PeriodicalIF":1.0,"publicationDate":"2022-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/02/JRPP-11-1.PMC9585804.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40677571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Lacosamide Add-on Therapy on Refractory Focal Epilepsies in Children and Adolescents: An Open-Label Clinical Trial. 拉科沙胺加药治疗儿童和青少年难治性局灶性癫痫的疗效:一项开放标签临床试验。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_86_21
Tayebeh Mohammadi, Jafar Nasiri, Mohammad Reza Ghazavi, Omid Yaghini, Neda Hoseini

Objective: Epilepsy is a chronic neurological disorder that affects 0.5%-1% of children. 30%-40% of patients are resistant to current anti-epileptic drugs. Lacosamide (LCM) appeared to be effective, safe, and well tolerated in children and adolescents. This study was aimed to evaluate whether LCM could be an effective add-on therapy in children with refractory focal epilepsies.

Methods: This study was conducted from April 2020 to April 2021 in Imam Hossein Children Hospital, Isfahan, Iran. We included 44 children aged 6 months to 16 years with refractory focal epilepsy (based on International League Against Epilepsy criteria). LCM was given in divided doses of 2 mg/kg/day, increasing by 2 mg/kg every week. The first follow-up visit was 6 weeks later, when all patients had reached the therapeutic dose.

Findings: The average age of the patients was 89.9 months. 72.5% of children had focal motor seizures. Evaluation of percent change in seizure frequency and duration before and after treatment showed a 53.22% reduction in seizure frequency and 43.72% reduction in seizure duration after treatment. Our study group tolerated LCM well, with few side effects. Headache, dizziness, and nausea were common side effects. In line with other studies, none of the suspected risk factors could predict response to LCM treatment.

Conclusion: LCM appears to be an effective, safe, and well-tolerated medication in children with uncontrolled drug-resistant focal epilepsy.

目的:癫痫是一种影响0.5%-1%儿童的慢性神经系统疾病。30%-40%的患者对目前的抗癫痫药物有耐药性。拉科沙胺(LCM)在儿童和青少年中似乎是有效、安全且耐受性良好的。本研究旨在评估LCM是否可以作为难治性局灶性癫痫患儿的有效补充治疗。方法:本研究于2020年4月至2021年4月在伊朗伊斯法罕伊玛目侯赛因儿童医院进行。我们纳入了44名6个月至16岁的难治性局灶性癫痫患儿(基于国际抗癫痫联盟的标准)。LCM分次给药,每天2 mg/kg,每周增加2 mg/kg。第一次随访时间为6周后,所有患者均达到治疗剂量。结果:患者平均年龄89.9个月。72.5%的儿童发生局灶性运动癫痫。治疗前后癫痫发作频率和持续时间的百分比变化评估显示,治疗后癫痫发作频率减少53.22%,癫痫发作持续时间减少43.72%。我们的研究组对LCM耐受性良好,几乎没有副作用。头痛、头晕和恶心是常见的副作用。与其他研究一致,没有任何可疑的危险因素可以预测对LCM治疗的反应。结论:LCM似乎是一种有效、安全且耐受性良好的药物,用于治疗无法控制的耐药局灶性癫痫患儿。
{"title":"Efficacy of Lacosamide Add-on Therapy on Refractory Focal Epilepsies in Children and Adolescents: An Open-Label Clinical Trial.","authors":"Tayebeh Mohammadi,&nbsp;Jafar Nasiri,&nbsp;Mohammad Reza Ghazavi,&nbsp;Omid Yaghini,&nbsp;Neda Hoseini","doi":"10.4103/jrpp.jrpp_86_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_86_21","url":null,"abstract":"<p><strong>Objective: </strong>Epilepsy is a chronic neurological disorder that affects 0.5%-1% of children. 30%-40% of patients are resistant to current anti-epileptic drugs. Lacosamide (LCM) appeared to be effective, safe, and well tolerated in children and adolescents. This study was aimed to evaluate whether LCM could be an effective add-on therapy in children with refractory focal epilepsies.</p><p><strong>Methods: </strong>This study was conducted from April 2020 to April 2021 in Imam Hossein Children Hospital, Isfahan, Iran. We included 44 children aged 6 months to 16 years with refractory focal epilepsy (based on International League Against Epilepsy criteria). LCM was given in divided doses of 2 mg/kg/day, increasing by 2 mg/kg every week. The first follow-up visit was 6 weeks later, when all patients had reached the therapeutic dose.</p><p><strong>Findings: </strong>The average age of the patients was 89.9 months. 72.5% of children had focal motor seizures. Evaluation of percent change in seizure frequency and duration before and after treatment showed a 53.22% reduction in seizure frequency and 43.72% reduction in seizure duration after treatment. Our study group tolerated LCM well, with few side effects. Headache, dizziness, and nausea were common side effects. In line with other studies, none of the suspected risk factors could predict response to LCM treatment.</p><p><strong>Conclusion: </strong>LCM appears to be an effective, safe, and well-tolerated medication in children with uncontrolled drug-resistant focal epilepsy.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"109-115"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/ef/JRPP-11-109.PMC10252575.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9611751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Selenium Supplementation on Lipid Profile, Anemia, and Inflammation Indices in Hemodialysis Patients. 补充硒对血液透析患者血脂、贫血和炎症指标的影响。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_68_22
Samaneh Assarzadeh, Sahar Vahdat, Shiva Seirafian, Morteza Pourfarzam, Shirinsadat Badri

Objective: Trace elements deficiency is common among end-stage renal disease (ESRD) patients due to excessive loss during dialysis and the lower intake secondary to loss of appetite. Selenium (Se) is a trace element that plays an important role in the radical scavenging system and helps the body defend against oxidative stress. This study aims to evaluate the effects of Se supplementation on lipid profile, anemia, and inflammation indices in ESRD patients.

Methods: Fifty-nine hemodialysis patients enrolled and were randomly divided into two groups. Two hundred microgram Se capsules once daily for the case group and matching placebo for the control group were administered for three months. Demographic data were collected at the study beginning. Uric acid (UA), anemia and inflammation indices, and lipid profiles were recorded at the beginning and the end of the study.

Findings: UA and UA-to-HDL (high-density lipoprotein) ratio decreased significantly in the case group (P < 0.001). The changes in lipid profile were not significant among both groups. Hemoglobin slightly increased in the case group, however, it decreased significantly in the control group (P = 0.031). High-sensitivity C-reactive protein (hs-CRP) decreased in the case group and increased in the control group, however, none of these changes were significant.

Conclusion: According to the results of this study, selenium supplementation in ESRD patients could reduce some risk factors related to their mortality, such as the ratio of uric acid to HDL. However, the changes related to lipid profile, hemoglobin level and hs-CRP biomarker were not significant.

目的:微量元素缺乏在终末期肾病(ESRD)患者中很常见,原因是透析过程中微量元素流失过多,以及继发于食欲不振的微量元素摄入减少。硒(Se)是一种微量元素,在自由基清除系统中起着重要作用,帮助身体抵御氧化应激。本研究旨在评估硒补充对ESRD患者血脂、贫血和炎症指标的影响。方法:59例血液透析患者随机分为两组。病例组每天服用200微克硒胶囊一次,对照组服用相应的安慰剂,持续三个月。在研究开始时收集了人口统计数据。在研究开始和结束时记录尿酸(UA)、贫血和炎症指标以及血脂。结果:病例组UA和UA / hdl(高密度脂蛋白)比值显著降低(P < 0.001)。两组患者血脂变化均不显著。病例组血红蛋白略有升高,对照组血红蛋白明显降低(P = 0.031)。高敏c -反应蛋白(hs-CRP)在病例组中下降,在对照组中升高,但这些变化都不显著。结论:根据本研究结果,ESRD患者补充硒可以降低一些与死亡率相关的危险因素,如尿酸与高密度脂蛋白的比值。然而,血脂、血红蛋白水平和hs-CRP生物标志物的变化不显著。
{"title":"Effect of Selenium Supplementation on Lipid Profile, Anemia, and Inflammation Indices in Hemodialysis Patients.","authors":"Samaneh Assarzadeh,&nbsp;Sahar Vahdat,&nbsp;Shiva Seirafian,&nbsp;Morteza Pourfarzam,&nbsp;Shirinsadat Badri","doi":"10.4103/jrpp.jrpp_68_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_68_22","url":null,"abstract":"<p><strong>Objective: </strong>Trace elements deficiency is common among end-stage renal disease (ESRD) patients due to excessive loss during dialysis and the lower intake secondary to loss of appetite. Selenium (Se) is a trace element that plays an important role in the radical scavenging system and helps the body defend against oxidative stress. This study aims to evaluate the effects of Se supplementation on lipid profile, anemia, and inflammation indices in ESRD patients.</p><p><strong>Methods: </strong>Fifty-nine hemodialysis patients enrolled and were randomly divided into two groups. Two hundred microgram Se capsules once daily for the case group and matching placebo for the control group were administered for three months. Demographic data were collected at the study beginning. Uric acid (UA), anemia and inflammation indices, and lipid profiles were recorded at the beginning and the end of the study.</p><p><strong>Findings: </strong>UA and UA-to-HDL (high-density lipoprotein) ratio decreased significantly in the case group (<i>P</i> < 0.001). The changes in lipid profile were not significant among both groups. Hemoglobin slightly increased in the case group, however, it decreased significantly in the control group (<i>P</i> = 0.031). High-sensitivity C-reactive protein (hs-CRP) decreased in the case group and increased in the control group, however, none of these changes were significant.</p><p><strong>Conclusion: </strong>According to the results of this study, selenium supplementation in ESRD patients could reduce some risk factors related to their mortality, such as the ratio of uric acid to HDL. However, the changes related to lipid profile, hemoglobin level and hs-CRP biomarker were not significant.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"103-108"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/e9/JRPP-11-103.PMC10252574.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9617631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Efficacy of an Oral Formulation of Glycyrrhiza glabra, Viola odorata, and Operculina turpethum as an Add-on Therapy for Mild-to-moderate Childhood Asthma: A Randomized Placebo-Controlled Clinical Trial. 甘草、堇菜和甲壳草口服制剂作为轻中度儿童哮喘附加治疗的疗效:一项随机安慰剂对照临床试验。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_77_22
Faezeh Rabbani, Mohsen Raeisi, Majid Keivanfar, Ali Saffaei, Ali Mohammad Sabzghabaee

Objective: We aimed to evaluate the efficacy of an oral combined tablet of Glycyrrhiza glabra, Viola odorata, and Operculina turpethum (Anti-Asthma®) as an add-on therapy for the relief of the severity of symptoms in mild-to-moderate childhood asthma.

Methods: This randomized placebo-controlled clinical trial was performed on 60 children and adolescents with chronic mild-to-moderate childhood asthma. Patients were randomly divided into cases who received Anti-Asthma® oral combined tablets 2 tablets twice dailt for 1 month and controls, received placebo tablets identically the same to Anti-Asthma® (2 tablets, twice daily, for 1 month) as add-ons to their standard therapy according to the guideline. The severity and frequency of cough attacks and shortness of breath, respiratory test indices (based on spirometry), and the extent of disease control and treatment adherence were measured clinically by validated questionnaires at the beginning and after the study.

Findings: Respiratory test indices improved and the severity of activity restriction decreased significantly in the cases compared to the controls However, the mean difference before and after the study was significantly different between the cases and controls only for the number and severity of coughs and the severity of activity restriction. In the scores of the Asthma Control Questionnaire, the cases group had a significant improvement compared to the controls.

Conclusion: Anti-Asthma® oral formulation may be effective as an adjunct add-on treatment in the maintenance therapy of mild-to-moderate childhood asthma.

目的:我们旨在评估一种口服甘草、堇菜和猪皮草联合片(抗哮喘®)作为缓解轻中度儿童哮喘症状严重程度的附加治疗的疗效。方法:本随机安慰剂对照临床试验对60例慢性轻中度儿童哮喘儿童和青少年进行研究。患者随机分为两组,一组服用抗哮喘®口服联合片剂2片,每日2次,持续1个月;另一组服用与抗哮喘®相同的安慰剂片剂(2片,每日2次,持续1个月),作为标准治疗的补充。在研究开始时和研究结束后,通过有效的问卷临床测量咳嗽发作和呼吸短促的严重程度和频率、呼吸试验指标(基于肺活量测定法)、疾病控制程度和治疗依从性。结果:与对照组相比,病例呼吸试验指标改善,限制活动严重程度明显降低,但仅咳嗽次数和严重程度以及限制活动严重程度与对照组相比,研究前后的平均差异有显著差异。在哮喘控制问卷的得分上,病例组与对照组相比有显著改善。结论:抗哮喘®口服制剂可作为轻中度儿童哮喘维持治疗的辅助治疗手段。
{"title":"The Efficacy of an Oral Formulation of <i>Glycyrrhiza glabra</i>, <i>Viola odorata</i>, and <i>Operculina turpethum</i> as an Add-on Therapy for Mild-to-moderate Childhood Asthma: A Randomized Placebo-Controlled Clinical Trial.","authors":"Faezeh Rabbani,&nbsp;Mohsen Raeisi,&nbsp;Majid Keivanfar,&nbsp;Ali Saffaei,&nbsp;Ali Mohammad Sabzghabaee","doi":"10.4103/jrpp.jrpp_77_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_77_22","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate the efficacy of an oral combined tablet of <i>Glycyrrhiza glabra, Viola odorata, and Operculina turpethum</i> (Anti-Asthma<sup>®</sup>) as an add-on therapy for the relief of the severity of symptoms in mild-to-moderate childhood asthma.</p><p><strong>Methods: </strong>This randomized placebo-controlled clinical trial was performed on 60 children and adolescents with chronic mild-to-moderate childhood asthma. Patients were randomly divided into cases who received Anti-Asthma<sup>®</sup> oral combined tablets 2 tablets twice dailt for 1 month and controls, received placebo tablets identically the same to Anti-Asthma<sup>®</sup> (2 tablets, twice daily, for 1 month) as add-ons to their standard therapy according to the guideline. The severity and frequency of cough attacks and shortness of breath, respiratory test indices (based on spirometry), and the extent of disease control and treatment adherence were measured clinically by validated questionnaires at the beginning and after the study.</p><p><strong>Findings: </strong>Respiratory test indices improved and the severity of activity restriction decreased significantly in the cases compared to the controls However, the mean difference before and after the study was significantly different between the cases and controls only for the number and severity of coughs and the severity of activity restriction. In the scores of the Asthma Control Questionnaire, the cases group had a significant improvement compared to the controls.</p><p><strong>Conclusion: </strong>Anti-Asthma<sup>®</sup> oral formulation may be effective as an adjunct add-on treatment in the maintenance therapy of mild-to-moderate childhood asthma.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"116-123"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/10/JRPP-11-116.PMC10252578.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9617628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation of the Effectiveness of an Herbal Formulation of Boswellia sacra Flueck. In Improving Cognitive and Behavioral Symptoms in Patients with Cognitive Impairment and Alzheimer's Disease. 乳香草中药制剂的疗效评价。改善认知障碍和阿尔茨海默病患者的认知和行为症状。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_73_22
Mahsa Panahishokouh, Maryam Noroozian, Fatemeh Mohammadian, Mahnaz Khanavi, Mahnaz Mirimoghaddam, Seyed Mehrdad Savar, Maryam Nikoosokhan, Hooshyar Honarmand, Niayesh Mohebbi

Objective: This study aimed to assess the efficacy of an herbal formulation based on Boswellia sacra in improving cognitive and behavioral symptoms in patients with mild cognitive impairment (MCI) and mild-to-moderate stages of Alzheimer's disease (AD).

Methods: A 3-month, parallel-group, placebo-controlled trial was implemented from October 2021 to April 2022. Patients with MCI and mild-to-moderate stages of AD aged above 50 years (n = 60; 40 women, 20 men) enrolled in the study using clinical diagnosis and a score of 10-30 on the mini-mental state examination (MMSE) test. They were assigned into two groups; one receiving a herbal formulation) include B. sacra, Melissa officinalis, Piper longum, Cinnamomum verum, and Physalis alkekengi) three times a day and the other receiving a placebo for 3 months. The main efficacy measures were the changes in cognitive domains based on the MMSE and changes in behavioral and psychiatric symptoms based on neuropsychiatric inventory (NPI) scores compared with baseline. Side effects were also recorded.

Findings: Results of this study showed significant differences between the two groups after 3 months in terms of all the assessed variables, including the overall result of the mean score of MMSE and NPI tests (P ≤ 0.001). The herbal formulation had the most considerable effects on the domains of orientation, attention, working memory, delay recall, and language of the MMSE test.

Conclusion: Herbal formulation based on B. sacra was significantly effective compared to a placebo in improving cognitive and behavioral symptoms in patients with MCI and mild-to-moderate AD.

目的:本研究旨在评估以乳香草为基础的中药制剂对轻度认知障碍(MCI)和轻中度阿尔茨海默病(AD)患者认知和行为症状的改善效果。方法:从2021年10月至2022年4月进行为期3个月的平行组安慰剂对照试验。年龄在50岁以上的轻度认知障碍和轻中度AD患者(n = 60;40名女性,20名男性)通过临床诊断和10-30分的迷你精神状态检查(MMSE)测试加入了这项研究。他们被分成两组;一组每天服用三次草药制剂(包括骶骨B., Melissa officinalis, Piper longum, Cinnamomum verum和Physalis alkekengi),另一组服用安慰剂,持续3个月。主要疗效测量是基于MMSE的认知领域的变化,以及基于神经精神量表(NPI)评分的行为和精神症状与基线相比的变化。同时也记录了副作用。结果:本研究结果显示,两组在3个月后的所有评估变量,包括MMSE和NPI测试平均得分的总体结果,均有显著差异(P≤0.001)。中药配方对MMSE测试的定向、注意、工作记忆、延迟回忆和语言等领域的影响最为显著。结论:与安慰剂相比,以骶骨为基础的草药制剂在改善轻度认知损伤和轻度至中度AD患者的认知和行为症状方面显着有效。
{"title":"Evaluation of the Effectiveness of an Herbal Formulation of <i>Boswellia sacra Flueck</i>. In Improving Cognitive and Behavioral Symptoms in Patients with Cognitive Impairment and Alzheimer's Disease.","authors":"Mahsa Panahishokouh,&nbsp;Maryam Noroozian,&nbsp;Fatemeh Mohammadian,&nbsp;Mahnaz Khanavi,&nbsp;Mahnaz Mirimoghaddam,&nbsp;Seyed Mehrdad Savar,&nbsp;Maryam Nikoosokhan,&nbsp;Hooshyar Honarmand,&nbsp;Niayesh Mohebbi","doi":"10.4103/jrpp.jrpp_73_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_73_22","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the efficacy of an herbal formulation based on <i>Boswellia sacra</i> in improving cognitive and behavioral symptoms in patients with mild cognitive impairment (MCI) and mild-to-moderate stages of Alzheimer's disease (AD).</p><p><strong>Methods: </strong>A 3-month, parallel-group, placebo-controlled trial was implemented from October 2021 to April 2022. Patients with MCI and mild-to-moderate stages of AD aged above 50 years (<i>n</i> = 60; 40 women, 20 men) enrolled in the study using clinical diagnosis and a score of 10-30 on the mini-mental state examination (MMSE) test. They were assigned into two groups; one receiving a herbal formulation) include <i>B. sacra, Melissa officinalis, Piper longum, Cinnamomum verum, and Physalis alkekengi</i>) three times a day and the other receiving a placebo for 3 months. The main efficacy measures were the changes in cognitive domains based on the MMSE and changes in behavioral and psychiatric symptoms based on neuropsychiatric inventory (NPI) scores compared with baseline. Side effects were also recorded.</p><p><strong>Findings: </strong>Results of this study showed significant differences between the two groups after 3 months in terms of all the assessed variables, including the overall result of the mean score of MMSE and NPI tests (<i>P</i> ≤ 0.001). The herbal formulation had the most considerable effects on the domains of orientation, attention, working memory, delay recall, and language of the MMSE test.</p><p><strong>Conclusion: </strong>Herbal formulation based on <i>B. sacra</i> was significantly effective compared to a placebo in improving cognitive and behavioral symptoms in patients with MCI and mild-to-moderate AD.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"91-98"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/1c/JRPP-11-91.PMC10252576.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse Drug Reactions in Psychiatry Outpatient Department of a Tertiary Care Hospital in Western Uttar Pradesh: An Observational Study. 西北方邦某三级医院精神科门诊药物不良反应:一项观察性研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-07-01 DOI: 10.4103/jrpp.jrpp_51_22
Jaspreet Kaur Sidhu, Kiran Jakhar, Deepti Chopra, Aditi Dhote, Vishakha Babber, Mohammad Shadman, C D Tripathi

Objective: Psychiatric disorders are chronic in nature which require medications for a long duration. These medications have been associated with many adverse events. Failure to recognize an adverse drug reaction (ADR) exposes the patient to continuing risk of ADR, leading to a significant impact on patient's quality of life. Thus, the present study carried out to identify the pattern of ADRs reported due to psychotropic medication.

Methods: This was a cross-sectional study conducted to analyze ADRs reported from the psychiatry department of a tertiary care teaching hospital from October 2021 to March 2022.

Findings: A total of 137 ADRs were identified from 102 patients. Majority of the ADRs were reported from antidepressants, with paroxetine being the leading offending drug. The central nervous system was most commonly affected, and dizziness (13.13%) was the most common ADR noted. On causality assessment, 97 ADRs (70.8%) were of "possible" type. Almost half of the patients with ADRs (47.5%) recovered spontaneously. No ADR encountered turned out to be fatal.

Conclusion: The present study revealed that the majority of ADRs reported from psychiatry OPD were mild in nature. We reinforce the identification of ADR is crucial in the hospital setting process as it gives an insight into the risk-benefit ratio for rational use of the drug.

目的:精神疾病是慢性的,需要长期的药物治疗。这些药物与许多不良事件有关。未能识别药物不良反应(ADR)会使患者面临持续的ADR风险,从而对患者的生活质量产生重大影响。因此,本研究旨在确定精神药物引起的不良反应报告的模式。方法:这是一项横断面研究,分析2021年10月至2022年3月一家三级护理教学医院精神科报告的不良反应。结果:102例患者共发现137例不良反应。据报道,大多数不良反应来自抗抑郁药,帕罗西汀是主要的致病药物。最常见的不良反应是中枢神经系统,头晕(13.13%)是最常见的不良反应。在因果关系评价中,97例adr为“可能”型,占70.8%。几乎一半的不良反应患者(47.5%)自发恢复。没有出现致命的不良反应。结论:本研究显示精神科门诊报告的大多数不良反应是轻微的。我们强调,在医院设置过程中,ADR的识别是至关重要的,因为它提供了对合理使用药物的风险-收益比的洞察。
{"title":"Adverse Drug Reactions in Psychiatry Outpatient Department of a Tertiary Care Hospital in Western Uttar Pradesh: An Observational Study.","authors":"Jaspreet Kaur Sidhu,&nbsp;Kiran Jakhar,&nbsp;Deepti Chopra,&nbsp;Aditi Dhote,&nbsp;Vishakha Babber,&nbsp;Mohammad Shadman,&nbsp;C D Tripathi","doi":"10.4103/jrpp.jrpp_51_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_51_22","url":null,"abstract":"<p><strong>Objective: </strong>Psychiatric disorders are chronic in nature which require medications for a long duration. These medications have been associated with many adverse events. Failure to recognize an adverse drug reaction (ADR) exposes the patient to continuing risk of ADR, leading to a significant impact on patient's quality of life. Thus, the present study carried out to identify the pattern of ADRs reported due to psychotropic medication.</p><p><strong>Methods: </strong>This was a cross-sectional study conducted to analyze ADRs reported from the psychiatry department of a tertiary care teaching hospital from October 2021 to March 2022.</p><p><strong>Findings: </strong>A total of 137 ADRs were identified from 102 patients. Majority of the ADRs were reported from antidepressants, with paroxetine being the leading offending drug. The central nervous system was most commonly affected, and dizziness (13.13%) was the most common ADR noted. On causality assessment, 97 ADRs (70.8%) were of \"possible\" type. Almost half of the patients with ADRs (47.5%) recovered spontaneously. No ADR encountered turned out to be fatal.</p><p><strong>Conclusion: </strong>The present study revealed that the majority of ADRs reported from psychiatry OPD were mild in nature. We reinforce the identification of ADR is crucial in the hospital setting process as it gives an insight into the risk-benefit ratio for rational use of the drug.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"99-102"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9e/41/JRPP-11-99.PMC10252573.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Research in Pharmacy Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1